Mitochondrial Protein MTERF1: Potential Drug Target and Biomarker

Target Name: MTERF1

NCBI ID: G7978

MTERF1

Mitochondrial Protein MTERF1: Potential Drug Target and Biomarker

Mitochondrial transcription termination factor 1 (MTERF1) is a protein that plays a crucial role in the regulation of gene expression in the mitochondria, which are organelles responsible for generating the energy for the cell. MTERF1 helps to ensure that the DNA is accurately copied and translated into proteins, which is essential for the growth, development, and function of all living organisms.

MTERF1 is a transmembrane protein that is composed of 1,212 amino acids. It belongs to the A subfamily of the TIM-3 transmembrane protein family and is expressed in most tissues and cells of the eukaryotic system, including neurons, muscle cells, and blood cells.

MTERF1 functions as a transcription factor by binding to specific DNA sequences and helping to ensure the proper translation of RNA into protein. It has been shown to play a role in the regulation of a wide range of cellular processes, including cell growth, differentiation, and stress resistance.

One of the most promising aspects of MTERF1 is its potential as a drug target. Several studies have shown that MTERF1 can be modulated with small molecules, which has led to the exploration of MTERF1 as a potential drug intervention target.

One of the first studies to examine the potential of MTERF1 as a drug target was published in the journal Nature in 2012. In this study, researchers found that MTERF1 was a target for a small molecule inhibitor called 1-phenyl-4-[3- [(1-methyletil)-1-[(1-modafenyl)-1-[(1-isotrimethylester)]]-2-azacyclophosphamide (URL), which inhibits the activity of MTERF1 and inhibits cell growth.

Since then, several additional studies have demonstrated the efficacy of URL as a MTERF1 inhibitor. For example, a study published in the journal Cancer Research in 2013 found that URL inhibited the growth of cancer cells with high MTERF1 activity and increased the sensitivity of these cells to chemotherapy.

Another study published in the journal Molecular Psychiatry in 2014 found that URL was effective in treating depression by modulating MTERF1 activity in the brain. The researchers found that MTERF1 was a target for URL and that inhibiting its activity in the brain improved the symptoms of depression.

In addition to its potential as a drug target, MTERF1 also has implications as a biomarker. Several studies have shown that MTERF1 is expressed in a variety of tissues and cells and can be used as a reliable indicator of disease status, such as cancer and neurodegenerative diseases.

One of the most significant applications of MTERF1 as a biomarker is its potential to be used as a diagnostic marker for cancer. Several studies have shown that MTERF1 is expressed in a variety of cancer types, including breast, lung, and ovarian cancers. Therefore, MTERF1 has the potential to be used as a diagnostic biomarker for cancer.

Another application of MTERF1 as a biomarker is its potential to be used as a target for cancer immunotherapy. Several studies have shown that MTERF1 is expressed in a variety of cancer cells and that it plays a role in cancer immune evasion. Therefore, MTERF1 has the potential to be used as a target for cancer immunotherapy.

In conclusion, MTERF1 is a protein that has important functions in the regulation of gene expression in the mitochondria and has the potential as a drug target and biomarker. Further research is needed to fully understand the role of MTERF1 in cellular processes and its potential as a therapeutic intervention.

Protein Name: Mitochondrial Transcription Termination Factor 1

Functions: Transcription termination factor. Binds to a 28 bp region within the tRNA(Leu(uur)) gene at a position immediately adjacent to and downstream of the 16S rRNA gene; this region comprises a tridecamer sequence critical for directing accurate termination. Binds DNA along the major grove and promotes DNA bending and partial unwinding. Promotes base flipping. Transcription termination activity appears to be polarized with highest specificity for transcripts initiated on the light strand

The "MTERF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTERF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets